In more than one instance the option indicated by Mirus’ analysis was not the one which would have led to the largest fee, but it was always the one which was demonstrated to be in the best long-term interests of the company’s shareholders.
- Allen L. Shulman, President, Interland
- Allen L. Shulman, President, Interland
Press Releases
Mirus Advises Optas, Inc. on Acquisition by Dendrite International, Inc.
09/12/2005 - Boston, Massachusetts
Mirus Capital Advisors, Inc., an investment bank specializing in middle market merger and acquisition advisory services, announced today that it has advised Optas, Inc., on the sale of its business to Dendrite International, Inc. (NASDAQ: DRTE) for $12 million of cash consideration. Under the agreement, the company, a provider of privacy-safe relationship marketing solutions for patients and physicians, becomes a division of Dendrite International, Inc. Located in Bedminster, NJ, Dendrite is a leading provider of sales, marketing and clinical solutions for the pharmaceutical industry.
"We have no doubt that we made the best possible choice in picking Peter Alternative and the team at Mirus," said Steve Smith, CEO of Optas. "They very quickly and thoroughly assimilated our business model and put the positioning together. They were bright and hard working and showed very high integrity. I would highly recommend Mirus to other companies."
According to a press announcement from Dendrite, the resulting integrated patient and prescriber-based marketing programs will enable pharmaceutical companies to reach physicians and consenting patients with consistent messages while maintaining adherence with federal and state regulations surrounding privacy (e.g., HIPAA - the Health Insurance Portability and Accountability Act).
Optas, formerly a private company headquartered in Woburn, MA, will be branded as Optas: a Division of Dendrite International. Founded in 1997, Optas’ leading-edge database marketing software and services allow pharmaceutical companies and health systems to communicate more effectively with customers. Marketers and their agencies use Optas solutions to improve acquisition and loyalty of their customers. Optas provides rapid deployment and a high return on marketing investment for its clients because of its customizable support of business processes.
Founded in 1986, Dendrite International serves the global life sciences and pharmaceutical industry. The firm has clients in more than 50 countries, including the world's top 20 pharmaceutical companies.
About Mirus Capital Advisors
Mirus Capital Advisors provides investment banking solutions to middle market corporations in targeted technology, manufacturing, and service industries. Additional information about the firm is available on its Web site www.merger.com.
return to press releases